16.02.2023 • NewsLonzabiotherapeuticsnon-GMP

Lonza to Add Early Development Services in US

Swiss CMDO Lonza said it will expand its Early Development Services (EDS) offering into North America with a new laboratory in Cambridge, Massachusetts, set to open in May this year.

The company said the expansion builds on its existing EDS activities at Cambridge, England, that on behalf of its customers support assessing, de-risking, and optimizing biotherapeutic drug candidates to maximize their chances of success.  If caught early, potential issues can be mitigated to reduce failure risks and improve speed to clinic for biotherapeutic candidates.

In the UK, Lonza provides services via a suite of in silico, early non-GMP protein expression and in vitro immunogenicity services. The new facility in Cambridge, Massachusetts will offer the same capabilities, namely early non-GMP expression and in vitro immunosafety assessment services.

At the location close to the Boston biotech community, the new Lonza facility will primarily serve preclinical stage small- to mid-sized companies in the development of biologic drug candidates from early development through to commercialization.

© Lonza
© Lonza

As, on average, only one in every thousand molecules succeeds beyond Phase 1 trials, early development services are essential in mitigating risks, reducing attrition and improving the quality and safety of biologic treatments, said Jean-Christophe Hyvert, president, Biologics at Lonza.

Yvette Stallwood, head of Early Development Services, said the new Massachsetts lab increases the Swiss company’s flexibility to support US biotechs in advancing potentially life-saving drug candidates from late-stage discovery into the clinic and help them manage the path to commercialization for their novel therapies.

Author: Dede Williams, Freelance Journalist

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.